Skip to main content

Table 3 Factors associated with major comorbidities in RA patients in multivariate logistic regression analyses

From: Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis

 

CVD

Fragility fracture

Malignancy

OR (95% CI)

P

OR (95% CI)

P

OR (95% CI)

P

Female

0.70 (0.53–0.92)

0.01*

2.58 (1.59–4.18)

<0.01*

1.26 (0.69–2.28)

0.45

Age, y

1.09 (1.07–1.10)

<0.01*

1.05 (1.04–1.06)

<0.01*

1.05 (1.03–1.07)

<0.01*

RA duration

 

 <5 years

1 (Ref)

NA

1 (Ref)

NA

1 (Ref)

NA

 ≥5 years

1.33 (1.03–1.72)

0.03*

1.95 (1.44–2.63)

<0.01*

0.97 (0.61–1.56)

0.91

RF/CCP+

1.30 (0.90–.88)

0.17

1.31 (0.86–2.00)

0.22

1.95 (0.89–4.27)

0.10

DAS28

0.97 (0.90–1.05)

0.48

1.04 (0.95–1.13)

0.44

1.03 (0.89–1.19)

0.70

GC ever

1.11 (0.86–1.44)

0.42

1.05 (0.78–1.40)

0.75

0.61 (0.37–1.00)

0.05

MTX ever

0.77 (0.60–1.00)

0.05*

0.96 (0.72–1.28)

0.78

0.57 (0.35–0.91)

0.02*

bDMARDs

1.04 (0.64–1.69)

0.86

1.79 (1.16–2.76)

<0.01*

0.15 (0.02–1.07)

0.06

  1. CVD cardiovascular disease, OR odds ratio, CI confidence interval, RA rheumatoid arthritis, NA not applicable, RF rheumatoid factor, CCP anti-citrullinated protein antibody, DAS28 disease activity score 28, GC glucocorticoid, MTX methotrexate
  2. * P < 0.05